Showing results (141-150 of 196) with videos related to
Sort By:
Pageof 20
Blood|May 16, 2009
Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantationMarina T van Leeuwen, Andrew E Grulich, Angela C Webster, et al.Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.Sexual Health|December 13, 2021
Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trialCurtis Chan, Doug Fraser, Stefanie Vaccher, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.HIV Medicine|September 29, 2021
Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012Ian K J Wong, Andrew E Grulich, Isobel Mary Poynten, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2023
Second Primary Cancers in People With HIV/AIDS: A National Data Linkage Study of Incidence and Risk FactorsPietro R Di Ciaccio, Marina T Van Leeuwen, Janaki Amin, et al.BMC Infectious Diseases|January 8, 2017
Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocolAndrew Lau, Fabian Kong, Christopher K Fairley, et al.The International Journal on Drug Policy|April 12, 2024
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage studyHeather Valerio, Alison D Marshall, Anna Conway, et al.Journal of Hepatology|September 10, 2014
Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatmentEsther J Aspinall, Sharon J Hutchinson, Naveed Z Janjua, et al.Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.Pageof 20